The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis
Kimball, Alexa Boer, MD, MPH, Yu, Andrew P., PhD, Signorovitch, James, PhD, Xie, Jipan, MD, PhD, Tsaneva, Magda, BA, Gupta, Shiraz R., PharmD, MPH, Bao, Yanjun, PhD, Mulani, Parvez M., PhD
Published in Journal of the American Academy of Dermatology (01.02.2012)
Published in Journal of the American Academy of Dermatology (01.02.2012)
Get full text
Journal Article
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Strober, Bruce E., MD, PhD, Poulin, Yves, MD, Kerdel, Francisco A., MD, Langley, Richard G., MD, Gu, Yihua, MS, Gupta, Shiraz R., PharmD, MPH, Okun, Martin M., MD, PhD, Papp, Kim A., MD, PhD
Published in Journal of the American Academy of Dermatology (01.04.2011)
Published in Journal of the American Academy of Dermatology (01.04.2011)
Get full text
Journal Article
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event–free response days in the CHAMPION trial
Reich, Kristian, MD, PhD, Signorovitch, James, PhD, Ramakrishnan, Karthik, MPH, Yu, Andrew P., PhD, Wu, Eric Q., PhD, Gupta, Shiraz R., PharmD, MPH, Bao, Yanjun, PhD, Mulani, Parvez M., PhD
Published in Journal of the American Academy of Dermatology (01.12.2010)
Published in Journal of the American Academy of Dermatology (01.12.2010)
Get full text
Journal Article